BioSpace News Archive

Late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® in children aged 1 to 11 years with active eosinophilic esophagitis will be presented at United European Gastroenterology Week 2022.

BerGenBio ASA announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

invIOs GmbH announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival Showcase and the Jefferies 2022 London Healthcare Conference.

TILT Biotherapeutics announces that the first US patient has been dosed in its ovarian cancer trial, using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication.

United Therapeutics Corporation announced that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis at sites outside the United States and Canada.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that The University of Tennessee Medical Center’s Cancer Institute has joined Caris’ Precision Oncology Alliance™.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) today announced it will be participating at the 2022 North American Spine Society (“NASS”) Annual Meeting, October 12-October 15, 2022 at McCormick Place – West Building in Chicago, Illinois at Booth #4604.

IASO Biotherapeutics and Cabaletta Bio, Inc. today announced that the companies entered into an agreement pursuant to which Cabaletta obtained from IASO Bio an exclusive, worldwide license to develop, manufacture and commercialize a clinically validated fully-human CD19 binder for use in product that is designed to modify T cells in treatment of autoimmune diseases.

HanAll Biopharma announced that its licensed partner in greater China, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd., a wholly-owned subsidiary of CSPC, a RBM 28 billion 2021 sales company based in China, for HanAll’s FcRn inhibitor batoclimab.

Samsung Biologics announced that its Plant 4 – the world’s largest single bio manufacturing plant – has commenced GMP operations this month.